BioNote

BioNote PEG

PEG Ratio (Price/Earnings-to-Growth) of BioNote (377740.KS) as of Oct 18, 2026.

PEG

-

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of BioNote is 2026 - . PEG Ratio (Price/Earnings-to-Growth) of BioNote was 2025 0.02 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioNote Stock analysis

What does BioNote do? BioNote Inc., headquartered in Hwaseong, South Korea, operates in the Health Care sector, specifically within Biotechnology. The company develops and manufactures rapid diagnostic kits for humans and animals, including immunochemical and fluorescence-based diagnostic products. It also produces raw materials such as antigens, antibodies, and enzymes, along with semi-finished products for diagnostic use. Listed on December 22, 2022, BioNote focuses on veterinary and human diagnostic solutions. BioNote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNote stock

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) BioNote since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s BioNote with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioNote

All Key Metrics — BioNote